Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults (CTCOVID-19)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04313127

Recruitment Status : Completed

First Posted : March 18, 2020

Last Update Posted : August 4, 2021

View this study on Beta.ClinicalTrials.gov

Sponsor:

Collaborators:

Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China

Jiangsu Province Centers for Disease Control and Prevention

Hubei Provincial Center for Disease Control and Prevention

Tongji Hospital

Information provided by (Responsible Party):

CanSino Biologics Inc.

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Completed
Actual Primary Completion Date :	January 20, 2021
Actual Study Completion Date :	February 20, 2021

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX, Wu SP, Wang BS, Wang Z, Wang L, Jia SY, Jiang HD, Wang L, Jiang T, Hu Y, Gou JB, Xu SB, Xu JJ, Wang XW, Wang W, Chen W. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020 Jun 13;395(10240):1845-1854. doi: 10.1016/S0140-6736(20)31208-3. Epub 2020 May 22.

To Top